Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
Luxa Biotechnology LLC (Luxa), a clinical -stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced the appointment of Keith Dionne, Ph.D. as Chief Executive Officer.
An early pioneer in the cell therapy field and a seasoned biotechnology executive, Dr. Dionne brings three decades of experience to Luxa and will be instrumental in advancing RPESC therapy to benefit patients with dry AMD and Geographic Atrophy (GA).
Dr. Dionne is an industry veteran with extensive experience leading U.S. and international biotechnology companies as well as multiple strategic alliances and acquisitions. He earned both his Ph.D. in Chemical Engineering and his M.S. in the Program for Technology Policy from the Massachusetts Institute of Technology.
Dry AMD is caused by the deterioration of macular RPE cells. As RPE cells degenerate and are not renewed, dry AMD results in impaired central vision and progressive blindness. There are currently no treatments available to reverse the damage or to restore the loss of vision. This is the gap that Luxa aims to fill.
The article
